Biomarkers of metastasis in endometrial cancer

The analysis of intratumoral microbiota and miRNA expression levels in endometrial cancer samples offers a novel approach to diagnose and predict metastasis, addressing the limitations of existing methods by providing a clear differentiation between healthy and cancerous states and identifying metastatic risk.

WO2024227966A1PCT designated stage expired Publication Date: 2024-11-07SERVICIO ANDALUZ DE SALUD (SAS) +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/ES2024/070268
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-03
Filing Date
2024-05-03
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current methods for diagnosing and predicting metastasis in endometrial cancer are inadequate, as they rely on image analysis after tumor spread, and there is a lack of understanding of the tumorigenic mechanisms, particularly regarding the microbiome's role in endometrial cancer development.

Method used

An in vitro method that analyzes the composition and relative abundance of intratumoral microbiota and specific microRNAs (miRNAs) in paraffinized tumor samples to differentiate between healthy controls, endometrial cancer patients, and those with metastasis, using techniques such as reverse transcription, sequencing, and bioinformatic analysis to classify individuals and predict metastasis.

Benefits of technology

This method effectively differentiates between healthy controls and endometrial cancer patients, as well as between those with and without metastasis, providing a predictive tool for metastasis and potentially improving prognosis and treatment response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000006_0001
    Figure IMGF000006_0001
  • Figure 00000024_0000
    Figure 00000024_0000
  • Figure 00000024_0001
    Figure 00000024_0001
Patent Text Reader

Abstract

The invention discloses biomarkers of metastasis in endometrial cancer and a method for the diagnosis and / or prognosis of metastasis development in endometrial cancer patients, said method being based on the relative abundance of the various genera and species in the isolated microbiota in endometrial samples, and on microRNA expression levels in the endometrial tissue.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] BIOMARKERS OF METASTASIS IN ENDOMETRIAL CANCER

[0002] DESCRIPTION

[0003] TECHNICAL FIELD

[0004] The present invention falls within the field of Medicine, specifically the field of oncological medical prognosis and diagnosis, and even more specifically refers to a method for prognosing the development of metastasis in patients with endometrial cancer based on the tumor microbiota, and on the expression levels of intratumoral microRNAs (miRNAs).

[0005] STATE OF THE ART

[0006] Endometrial cancer (EC) is a commonly diagnosed gynecological cancer in developed countries and accounts for approximately 7% of new cancer cases and 4% of cancer-related deaths in women. Most women diagnosed at an early stage have a prolonged survival time; however, those with high-risk histopathology or advanced stages have a poor prognosis. Early diagnosis, reasonable prognostic assessment, and timely intervention are important. Currently, the development of metastases is identified through imaging analysis once the primary tumor has spread.

[0007] The causative or triggering agents of endometrial cancer remain elusive despite ongoing research along the PI3K / PTEN / mTOR / HIF axis in type I or endometrioid endometrium (EEC), and the p53 tumor suppressor system in type II or non-endometrioid endometrial cancer (NEEC) [1], Host genetics explain only 20% of endometrial cancer incidence through microsatellite instability (MI) or aerobic glycolysis abnormalities. Efforts to identify the cause of the remaining 80% of cases have resulted in studies of several environmental and host factors including hormones, obesity, and diabetes. However, these alone do not address the question of the tumorigenic mechanism.One of the emerging modulators between environmental triggers and genetic expression is the microbiome [2-4], Emerging evidence confirmed the existence of a microbial community within the endometrial cavity whose composition can vary according to different gynecological conditions, including endometrial cancer [5], The endometrial microbiota profile is composed of species of the genus Lactobacillus, the most predominant, Bacteroides, Pelomonas, Pseudomonas, Acinetobacter, Vagococcus, Sphingobium, Rhodococcus, Phyllobacterium and Bifidobacterium [6], There is abundant evidence suggesting a participation of the microbiota in the development of cancer. In relation to endometrial cancer, the association of Atopobium vaginae and Porphyromonas spp. is known.with the development of endometrial cancer, especially when vaginal pH is high [2], On the other hand, NGS-based RNA sequencing (RNA-seq) provides a reliable and effective screening method to identify novel biomarkers and better understand cancer biology. Despite efforts made by The Cancer Genome Atlas (TCGA) to understand the transcriptome of endometrial cancer through RNA-seq data, there is almost no transcriptome information of differentially expressed genes between endometrial cancer versus normal endometrial tissue.

[0008] MicroRNAs or miRNAs play an important role in oncogenic activation due to their involvement in cellular processes and their ability to act as oncogene or tumor suppressor. They are involved in the development of several types of cancer, including colorectal, breast, ovarian and endometrial cancer [7]. miRNAs are small endogenous non-coding RNAs with about 18-25 nucleotides in length, capable of modulating the expression of complementary messenger RNAs. They negatively regulate (inhibit) gene expression either by inhibiting translation or cleaving messenger RNA. Therefore, miRNAs are post-transcriptional regulators that bind to complementary sequences of mRNA transcripts by pairing with the untranslated region (3'-UTR), which generally results in translational repression or degradation of the target resulting in gene silencing.They are involved in the regulation of most molecular processes, and there is consistent scientific evidence about their relationship with various metabolic processes, including apoptosis, cell proliferation and differentiation, and developmental timing.

[0009] Under a standard nomenclature system, experimentally confirmed miRNAs are named as follows: the prefix "mir", followed by a hyphen and a number. The uncapitalized "mir-" refers to the pre-mRNA, while an uppercase "m¡R-" refers to the mature form. miRNAs with nearly identical sequences (except for one or two nucleotides) are annotated with an additional lowercase letter, e.g., m¡R-99a. Pre-m¡RNAs that lead to 100% identical mature miRNAs but are located at different loci in the genome are indicated with an additional hyphen-number suffix. Species of origin may be designated with a three-letter prefix, with hsa being the most common for human miRNAs (Homo sapiens). In the context of this document, where all individualized miRNAs are human miRNAs, the "hsa-" prefix is ​​sometimes omitted.When two mature miRNAs originate from opposite arms of the same pre-mRNA, they are denoted by a -3p or -5p suffix, such as m¡R-142-3p. When relative expression levels are known, an asterisk after the name indicates a miRNA expressed at low levels relative to the miRNA on the opposite arm of a hairpin. miRNA sequences can be accessed at http: / / www.mirbase.org.

[0010] The interaction between miRNAs and bacteria could influence the host response. Indeed, an alteration of the microbiota and miRNAs is capable of causing altered production of oncogenes and / or tumor suppressor genes, which can induce the onset and progression of cancer. Helicobacter pylory infection was the first example of altered miRNA expression profile due to a bacterial pathogen. Furthermore, several miRNAs, including m¡R-16, m¡R-146a and m¡R-155, were upregulated by Helicobacter pylori infection [8]. Mycobacterium tuberculosis is another example of the important role that miRNAs play in host-pathogen interactions. Broad changes in the expression profile of miRNAs have been reported after infection with Mycobacterium tuberculosis, especially those involved in the regulation of inflammatory responses [9].

[0011] BRIEF DESCRIPTION OF THE INVENTION The present invention demonstrates for the first time the existence of a relationship between intratumoral microbiota, intratumoral miRNAs and endometrial cancer. Thanks to the differences in the composition of the initial intratumoral microbiota, the method of the invention makes it possible to differentiate between healthy controls and patients with endometrial cancer, endometrioid and non-endometrioid patients, and patients with metastases and those without. In addition to the analysis of the composition of the microbiota, the analysis of the differences in the expression levels of certain intratumoral microRNAs (miRNAs) that act as biomarkers in paraffin-embedded tumor samples from patients with different subtypes of endometrial cancer, makes it possible to discriminate between patients with metastases and those without.

[0012] DETAILED DESCRIPTION OF THE INVENTION

[0013] A first aspect of the invention describes an in vitro method for obtaining data useful for diagnosing and / or predicting endometrial cancer, its degree of severity and its metastasis, hereinafter "method of the invention" which comprises a) isolating the genetic material of the microbiota present in a previously isolated sample of endometrium, b) taxonomically identifying the isolated genetic material and quantifying the relative abundance of each of the taxa identified in the sample.

[0014] Preferably, the isolation of the genetic material from the microbiota present in the previously isolated endometrial sample is carried out by isolating genetic material, which may be DNA or RNA, preferably RNA. Preferably, the taxonomic identification of the isolated genetic material and the quantification of the relative abundance of the detected taxa are carried out by reverse transcription reaction to cDNA, amplification of bacterial 16S rRNA, creation of libraries with said cDNA, its sequencing, and subsequent bioinformatics analysis.Another aspect of the invention relates to an in vitro method for diagnosing and / or prognosing endometrial cancer comprising the method of the invention, and further comprising c) classifying the individual into the group of individuals suffering from endometrial cancer when the relative abundance in the sample of the genera Lactobacillus, Roseburia, AF12, Turicibacter, Oscillospira, Blautia, Allubaculum, Ruminococcus, Akkermancia, Butyricimonas, Bifidobacterium, Parabacteroides and / or Mucispirillum is significantly lower compared to the group of healthy controls, and / or Micrococcus, Propionibacterium, Staphylococcus, Pantoea, Vibrio, Lawsonia, Sphingomonas, Rothia, Corynebacterium, Ralstonia, Paracoccus and / or Pelomonas is significantly higher with respect to the samples of healthy control individuals.In a preferred embodiment of this aspect of the invention, the in vitro method for diagnosing and / or prognosing endometrial cancer classifies the individual into the group of individuals suffering from endometrial cancer when the relative abundance of the genera Micrococcus, Staphylococcus and Propionibacterium is greater with respect to the samples from healthy control individuals.

[0015] Another aspect of the invention relates to an in vitro method for diagnosing and / or prognosing endometrial cancer comprising the method of the invention, and further comprising c) classifying the individual into the group of individuals suffering from endometrial cancer when the relative abundance in the sample of the species Prevotella copri, Lactobacillus reuteri, Bacteroides acidifaciens, Parabacteroides distasonis and / or Mucispirillum schaedleri is significantly lower with respect to the samples from healthy control individuals, and / or Micrococcus luteus, Staphylococcus epidermidis, Propionibacterium granulosum, Propionibacterium acnes, Photobacterium angustum and / or Rothia mucilaginosa is significantly higher with respect to the samples from healthy control individuals.

[0016] Another aspect of the invention relates to an in vitro method for diagnosing and / or prognosing the degree of severity of endometrial cancer comprising the method of the invention, and further comprising c) classifying the individual into the group of individuals suffering from type II endometrial cancer or non-endometrioid carcinoma, when the relative abundance in the sample of the genera Prevotella, Faecalibacterium, Bifidobacterium, Ruminococcus, Oscillospira, Blautia, Pelomonas, Lactobacillus and / or Fusobacteria is significantly lower compared to the group presenting endometrioid or type I tumors, and / or Micrococcus, Staphylococcus, Acinetobacter, Paracoccus, Corynebacterium, Propionibacterium, Porphyromonas and / or Bacteroides is significantly higher compared to the group presenting endometrioid or type I tumors.

[0017] Another aspect of the invention relates to an in vitro method for diagnosing and / or prognosing the degree of severity of endometrial cancer comprising the method of the invention, and further comprising c) classifying the individual into the group of individuals suffering from type II endometrial cancer or non-endometrioid carcinoma, when the relative abundance in the sample of the species Prevotella copri, Faecalibacterium prausnitzii, Bacteroides uniformis, Ruminococcus bromii, Bacteroides plebeius, Oscillospira guillermondii and / or Bacteroides caccae is significantly lower compared to the group presenting endometrioid or type I tumors, and / or Micrococcus luteus, Propionibacterium granulosum and / or Propionibacterium acnes is significantly higher compared to the group presenting endometrioid or type I tumors.

[0018] Another aspect of the invention relates to an in vitro method for diagnosing and / or predicting metastasis in patients with endometrial cancer comprising the method of the invention, and further comprising c) classifying the individual into the group of individuals who have developed or are at risk of developing metastasis, when the relative abundance in the sample of the genera Blautia, Faecalibacterium, Prevotella, Ruminococcus, Bifidobacterium, Bacteroides, Lactobacillus and / or Oscillospira is significantly lower compared to the group that does not present metastasis, and / or Micrococcus, Pantoea, Propionibacterium, Paracoccus, Acinetobacter, Staphylococcus, Fusobacterium, Ralstonia and / or Corynebacterium is significantly higher compared to the group that does not present metastasis.Another aspect of the invention relates to an in vitro method for diagnosing and / or predicting metastasis in patients with endometrial cancer comprising the method of the invention, and further comprising c) classifying the individual into the group of individuals who have developed or are at risk of developing metastasis, when the relative abundance in the sample of the species Prevotella copri, Faecalibacterium prausnitzii, Bacteroides plebeius and / or Bacteroides uniformis is significantly lower compared to the group that does not present metastasis, and / or Propionibacterium granulosum, Propionibacterium acnes, Staphylococcus epidermis and / or Micrococcus luteus is significantly higher compared to the group that does not present metastasis.

[0019] Another aspect of the invention relates to an in vitro method for obtaining data useful for diagnosing and / or prognosing endometrial cancer, its degree of severity and metastasis, which comprises the method of the invention, and which also comprises measuring in a previously isolated sample of endometrium the expression levels of one or more of the following miRNAs:

[0020] Table 1: miRNA sequences of the invention.

[0021] Another aspect of the invention relates to an in vitro method for diagnosing and / or prognosing the degree of severity of endometrial cancer comprising the method for diagnosing and / or prognosing the degree of severity of endometrial cancer described above, where an additional factor for classifying the individual in the group of individuals suffering from type II endometrial cancer or non-endometrioid carcinoma is that the previously isolated sample of endometrium presents significantly decreased levels of expression of m¡R20b-5p and m¡R149-5p compared to the group presenting endometrioid or type I tumors.

[0022] Another aspect of the invention relates to an in vitro method for diagnosing and / or predicting metastasis in patients with endometrial cancer comprising the method for diagnosing and / or predicting metastasis in patients with endometrial cancer described above, where an additional factor for classifying the individual in the group of individuals who are at risk of developing metastasis or have already developed metastasis is that the previously isolated sample of endometrium presents increased levels of expression of m¡R20b-5p and a decrease in the expression of m¡R10a-5p with respect to non-metastatic tumors.

[0023] In a preferred embodiment of this aspect of the invention, the relative abundance in the sample compared to the group not showing metastasis is, at the genus level, significantly lower for Bifidobacterium, Faecalibacterium, and Lactobacillus and significantly higher for Fusobacterium, Micrococcus while at the species level, significantly lower for Bifidobacterium longum, Faecalibacterium prausnitzii, and Lactobacillus mucosae and significantly higher for Fusobacterium nucleatum, Micrococcus luteus.

[0024] In a preferred embodiment of the described methods where the expression levels of miRNAs are involved, these are obtained by: (i) a method for generating miRNA profiles, such as a microarray, and / or (ii) a method comprising PCR (polymerase chain reaction), such as real-time PCR or RT-PCR and / or (iii) a Northern Blot and / or (iv) an immunoassay, such as an immunohistochemistry method or an ELISA-based method.

[0025] In vitro determination of expression levels is performed using any of the techniques known in the state of the art. Preferably, the techniques are selected from the list consisting of a gene profiling method, such as a microarray, or a next-generation sequencing panel; and / or a method comprising PCR, such as real-time PCR or RT-PCR; and / or Northern blotting; and / or an immunohistochemical method; and / or an ELISA-based method.

[0026] A microarray is an array on a solid substrate (usually a glass slide or a silicon thin film cell) that analyzes large amounts of biological material, in the present case a large number of different miRNAs or, preferably, their reverse DNA transcripts, which are detectable by specific probes immobilized on the solid substrate.

[0027] A Northern blot involves the use of electrophoresis to separate RNA samples by size and subsequent detection with a hybridization probe complementary to (part of) the RNA target sequence of interest.

[0028] The quantification of miRNA expression is preferably performed by RT-PCR. Reverse transcription PCR, or RT-PCR, allows the detection and amplification of RNA. RNA is reverse transcribed into complementary DNA (cDNA) using reverse transcriptase. The first step in RT-PCR is the synthesis of a DNA / RNA hybrid. Reverse transcriptase also has an RNase H function, which degrades the RNA portion of the hybrid. The single-stranded DNA molecule is then completed into cDNA by the reverse transcriptase activity of DNA-dependent DNA polymerase. From here, the standard PCR procedure is used to amplify the cDNA. The ability to reverse RNA into cDNA using RT-PCR has many advantages, as RNA is single-stranded and very unstable, making it difficult to work with.

[0029] In the method of the present invention, miRNA expression can be normalized, preferably relative to the expression of another RNA molecule. Normalization methods are well known in the art.

[0030] Another aspect of the invention relates to a method for predicting the therapeutic response to an anti-metastasis treatment in patients with endometrial cancer. Another aspect of the invention relates to a kit or device comprising at least one or more oligonucleotides capable of hybridizing with one or more of the miRNAs in Table 1 under stringent conditions. Preferably, it comprises at least one or more oligonucleotides capable of hybridizing with m¡R20b-5p and m¡R10a-5p and more preferably with all of the miRNAs in Table 1, m¡R149-5p, m¡R10a-5p, m¡R20b-5p, m¡R30a-3p and m¡R342-5p, simultaneously under stringent conditions.

[0031] It is preferred that said oligonucleotide(s) be capable of doing so under stringency conditions. In a preferred embodiment, one or more of said one or more oligonucleotides (preferably DNA) are further defined by the following probes or primers: hsa-m¡RXX-m¡RCURY LNA miRNA measured with syber, LNA™ PCR specific primers. Stringency is a term used in hybridization experiments. Stringency reflects the degree of complementarity between the oligonucleotide and the nucleic acid (which in this case is the miRNA to be detected); the higher the stringency, the higher the percentage of homology between the probe and the nucleic acid bound to the filter. The person skilled in the art is well aware that temperature and salt concentrations have a direct effect on the results obtained. It is recognized that the hybridization results are related to the number of degrees below the Tm (melting temperature) of the DNA on which the experiment is performed.Stringent conditions are often defined as a wash with 0.1X SSC (saline-sodium citrate (SSC) buffer at 65°C. (SSC is typically provided as a 20X stock solution, consisting of 3 M sodium chloride and 300 mM trisodium citrate (adjusted to pH 7.0 with HCl)). In particular embodiments, the kit is selected from (a) a kit suitable for microarray analysis, (b) a kit suitable for PCR, (c) a kit suitable for Northern blotting, (d) a kit suitable for immunoassay. Two or more of these embodiments may also be combined, such that the kit may comprise, for example, both (a) and (c).

[0032] In one embodiment, the kit comprises a microarray. An RNA microarray is an array on a solid substrate (generally a glass slide or a silicon thin-film cell) that analyzes large quantities of different RNAs (in this case miRNAs), which can be detected by specific probes immobilized on spots of the solid substrate. Each spot contains a specific nucleic acid sequence, typically a DNA sequence, known as probes (or reporters). While the number of spots is not limited, there is a preferred embodiment in which the microarray is adapted to the methods of the invention. In one embodiment, such a custom microarray comprises fifty spots or fewer, such as thirty spots or fewer, including twenty spots or fewer.

[0033] In another embodiment thereof, it is a kit suitable for PCR, this PCR being typically a real-time quantitative PCR (RQ-PCR), a sensitive and reproducible gene expression quantification technique. In this case, it is desired that the kit additionally comprises a polyT oligonucleotide primer in addition to the oligonucleotide(s) of the kit. The polyT oligonucleotide primer can be used together with the oligonucleotide(s) of the invention for priming PCR, after polyadenylation of the isolated miRNAs by methods known to those skilled in the art, such as the use of poly-(A) polymerase and ATP. These reagents may optionally be included in the kit.

[0034] In another embodiment thereof, the kit is suitable for performing a Northern blot, which involves the use of electrophoresis to separate RNA samples by size and subsequent detection with an oligonucleotide(s) (hybridization probe) complementary to (part of) the target RNA sequence of interest.

[0035] In another embodiment, the oligonucleotides, primers, probes, or antibodies are modified or labeled, for example, but not limited to, by radioactive or immunological labeling. Thus, preferably, the oligonucleotides have modifications in some of their nucleotides, such as, but not limited to, nucleotides that have one of their atoms with a radioactive isotope, usually 32P or tritium, immunologically labeled nucleotides, such as with a digoxigenin molecule, and / or immobilized on a membrane. Several possibilities are known in the state of the art.

[0036] The kit or device of the invention can be used in the method of the invention in any of its embodiments, although its use is not particularly limited.

[0037] The kit or device of the invention may comprise controls, program instructions and information necessary to carry out any of the methods of the invention.

[0038] Another aspect of the invention relates to computer-readable storage media comprising program instructions capable of causing a computer to perform the steps of any of the methods of the invention. The invention also extends to computer programs adapted to enable any processing medium to carry out the methods of the invention. Such programs may take the form of source code, object code, an intermediate source of code, and object code, for example, in partially compiled form, or in any other form suitable for use in implementing the processes according to the invention. Computer programs also encompass cloud applications based on this method. In particular, the invention encompasses computer programs arranged on or within a medium. The carrier may be any entity or device capable of supporting the program.When the program is embodied in a signal that can be transported directly by a cable or other device or medium, the carrier may be constituted by said cable or other device or medium. Alternatively, the carrier could be an integrated circuit on which the program is embedded, the integrated circuit being adapted to execute, or to be used in the execution of, the corresponding processes.

[0039] For example, the programs could be embedded in a storage medium, such as a ROM, a CD-ROM, or a semiconductor ROM, a USB memory stick, or a magnetic recording medium, e.g., a floppy disk or a hard drive. Alternatively, the programs could be supported by a transmissible carrier signal. For example, it could be an electrical or optical signal that could be transported through an electrical or optical cable, by radio, or by any other means. The invention also extends to computer programs adapted to allow any processing medium to carry out the methods of the invention. Such programs may take the form of source code, object code, intermediate source code, and object code, e.g., in partially compiled form, or in any other form suitable for use in implementing the processes according to the invention.Computer programs also encompass cloud applications based on this method. Therefore, another aspect of the invention relates to a computer-readable storage medium comprising program instructions capable of causing a computer to perform the steps of any of the methods of the invention.

[0040] Another aspect of the invention relates to a transmissible signal comprising program instructions capable of causing a computer to carry out the steps of any of the methods of the invention.

[0041] In the context of the present invention, the terms "subject," "patient," or "individual" are used interchangeably herein to refer to all animals classified as mammals and include, but are not limited to, domestic and farm animals, primates, and humans, e.g., humans, non-human primates, cows, horses, pigs, sheep, goats, dogs, cats, or rodents. Preferably, the subject is a female human of any age or race.

[0042] Throughout the description and claims, the word "comprises" and its variations are not intended to exclude other technical features, accessories, components, or steps. For those skilled in the art, other objects, advantages, and features of the invention will become clear in part from the description and in part from the practice of the invention. The following examples and drawings are provided for illustrative purposes and are not intended to limit the present invention.

[0043] An "isolated biological sample" includes, but is not limited to, cells, tissues, and / or biological fluids from an organism, obtained by any method known to a person skilled in the art. Preferably, the isolated biological sample is an endometrial sample.

[0044] The terms “one or more” or “at least one” or “several,” as used herein, include one and the individualized specification of any number that is more than one, such as two, three, four, five, six, etc.

[0045] DESCRIPTION OF THE FIGURES

[0046] Figure 1. Endometrial microbiota richness and diversity in healthy controls (Control) and patients with endometrial cancer (Patient). (A) Shannon index (p = 0.00754). (B) Chaol index (p = 0.024). (C) Simpson index (p = 0.0037). (D) Observed species index (p = 0.0010). (E) Bray-Curtis beta diversity analysis (p < 0.002).

[0047] Figure 2. Relative abundance at the phylum (A), family (B), genus (C), and species (D) levels of differentially abundant bacteria in endometrial samples from healthy controls and endometrial cancer patients. * p < 0.05, ** p < 0.001. Figure 3. Richness and diversity of endometrial microbiota in endometrioid and non-endometrioid tumors. (A) Simpson index (p = 0.00027). (B) Chaol index (p = 0.0024). (C) Shannon index (p = 0.000136). (D) Observed species index (p = 0.00248). (E) Bray-Curtis beta diversity analysis (p = 0.0057). Figure 4. Relative abundance at the phylum (A), family (B), genus (C), and species (D) levels of differentially abundant bacteria in endometrioid and non-endometrioid tumors. * p < 0.05, ** p < 0.001.

[0048] Figure 5. Diversity of the endometrial microbiota according to the Shannon index (A) and extent according to the Chaol index (B) between metastatic and non-metastatic endometrial tumors. (C) Clustering of endometrial bacterial communities according to both study groups using the Bray-Curtis dissimilarity matrix. Relative abundance of bacterial phyla (D), species (E) and genera (F) between metastatic and non-metastatic endometrial tumors.

[0049] Figure 6. Differentially expressed miRNAs in endometrioid and non-endometrioid tumor samples. **p < 0.001, *p < 0.05.

[0050] Figure 7. Differentially expressed miRNAs in metastatic and non-metastatic tumors. **p < 0.001, *p < 0.05.

[0051] Figure 8. Random Forest analysis to distinguish between endometrial cancer patients developing metastases based on intratumoral microbiota and miRNA profiles. (A) Receiver Operating Characteristic (ROC) curve and area under the curve (AUC) were generated to predict the presence of metastases in endometrial cancer patients based on the predominant intratumoral microbial species (Bifidobacterium longum, Faecalibacterium prausnitzii, Fusobacterium nucleatum, Micrococcus luteus and Lactobacillus mucosae), (B) intratumoral expression of the five miRNAs in Table 1, and (C) joint modeling of the 5 intratumoral species and 2 miRNAs (m¡RNA20b-5p and m¡RNA10a-5p).

[0052] EXAMPLES OF IMPLEMENTATION The study included 68 postmenopausal women aged 53–80 years, 58 of whom had been diagnosed with grade I–III endometrial cancer at the Virgen de la Victoria Hospital, and 10 healthy controls. Each patient gave informed consent, and the study was approved by the Research Ethics Committee of the Virgen de la Victoria Hospital. The inclusion criteria for participants were: (a) postmenopausal women aged 46–80 years; (b) subjects who had undergone hysterectomy using a standard surgical approach for any suspicion of benign disease and (c) endometrial cancer stage I–IV.Exclusion criteria were: (a) history of any previous gynecological cancer; (b) pregnant and lactating women; (c) women who used antibiotics, probiotics, and prebiotics within 3 months prior to study inclusion; (d) history of genital tract infection within 3 months prior to inclusion; and (e) patients who received preoperative chemotherapy or radiotherapy. Clinicopathological data collected included obesity and metastasis for each patient. All patients underwent hysterectomy for benign disease or endometrial cancer, and formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples were collected.

[0053] Histopathological study: Microtome sections were made from formalin-fixed, paraffin-embedded (FFPE) tissue samples and stained with hematoxylin-eosin to identify the tumor area and cellularity. For hematoxylin-eosin staining, tissue samples were pre-deparaffinized with xylene and immersed in various washing solutions containing water and ethanol before and after hematoxylin-eosin staining. The tumor area indicated by the pathologist was selected in each block, and the number of sections made for RNA extraction depended on the tumor cellularity of each sample. RNA extraction: Endometrial RNA was isolated from formalin-fixed, paraffin-embedded (FFPE) tissue samples using the RecoverAII total nucleic acid isolation kit (Ambion, life technologies).Sections cut from FFPE (a maximum of four at 20 pm, or eight at 10 pm), placed in 1.5 mL microcentrifuge tubes, were treated with 1 mL of 100% xylene and heated for 3 minutes at 50°C to completely remove paraffin from the sections. All samples were centrifuged for 2 minutes at room temperature and maximum speed to pellet the tissue. Each sample pellet was washed twice with 1 mL of 100% ethanol and air-dried to remove residual ethanol. Digestion buffer and protease were added to each sample, and the samples were incubated at 50°C overnight to digest the covalently linked protein to the RNA. The samples were then subjected to a 15-minute incubation at 80°C to stop the digestion and protease. To isolate the nucleic acid, isolation additive / ethanol was added to each sample, and the mixture was passed through a filter cartridge. Two washes were performed, followed by centrifugation to remove residual liquid.Before final purification, the samples were treated with DNase to remove DNA. Three washes were then performed with a final centrifugation to remove all residual fluid. Finally, the RNA was eluted in 60 pl of elution buffer. The total RNA concentration and purity (260 / 280 / 260 / 230) were estimated using the Nanodrop spectrophotometer.

[0054] Reverse transcription reaction: cDNA or complementary DNA was synthesized from the isolated RNA by a reverse transcription reaction using PrimeScript RT Master Mix Samples (Perfect Real Time) (TaKaRa). For reverse transcription, 2 pl of 5X PrimeScript RT Master Mix and 8 pl of RNA (500 ng for all samples) diluted in RNase-free distilled water were mixed in the reaction and incubated in a thermocycler for 15 minutes at 37°C for reverse transcription and 5 seconds at 85°C for heat inactivation.

[0055] Endometrial tumor microbiota sequencing: To create the libraries, cDNA samples (5ng / ul) were amplified using primers encoding the V2-4-8 and V3-6, 7-9 hypervariable regions of bacterial 16S rRNA using the 16S Metagenomics Kit (Thermo Fisher Scientific). PCR products derived from the amplification of the hypervariable regions were purified using AMPure® XP beads (Beckman Coulter Genomics) to remove any remaining primers or primer dimers. Subsequently, for library creation, amplicons were treated using the Ion Plus fragment Library kit (Thermo Fisher Scientific) and identification codes were added using the Ion Xpress Barcode Adapters 1-96 kit (Thermo Fisher Scientific). The created libraries were purified using AMPure® XP beads (Beckman).The libraries were emulsified and sequencing was carried out using the Ion 520 TIW 530™ Kit-Chef (Thermo Fisher Scientific) and the Ion 520 chip (Ion 520™ Chip Kit), utilizing the Ion Chef system platform and Ion Torrent S5™. Bioinformatics analysis: Analysis of 16S amplicons was performed with QIIME2 (version 2-2019.4). For quality filtering and denoising of the raw data, the DADA2 pipeline and the q-dada2 plugin were used. The DADA2 pipeline generated sequence variants, which were integrated into a single table using the q2-feature-table plugin. The Open Reference Clustering method with Greengenes version 13_8 was used to cluster all sequence variants in the merged table into operational taxonomic units (OTUs) with 97% similarity to the OTU reference sequences.

[0056] MAFFT (q2-alignment) was used for OTU alignment and subsequent phylogeny construction with fasttree 2 (q2-phylogeny). The q2-feature-classifier classify-sklearn naive Bayes taxonomy classifier was used to assign taxonomy to OTUs. After sample rarefaction to 999 sequences per sample, the q2 diversity plugin was used to estimate the alpha diversity metric (Shannon and Chaol), the beta diversity metric (Bray-Curtis dissimilarity), and principal coordinate analysis (PCoA). The Kruskal-Wallis test was used to estimate the significance of alpha diversity, while the significance of beta diversity was estimated using the nonparametric ANOSIM test. A LEfSe analysis was also performed using the default parameters LDA=4.0, p<0.05 to detect differentially abundant taxa in endometrial cancer patients and healthy controls.Metagenome functions were predicted using Phylogenetic.

[0057] Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) by selecting OTUs paired with the Greengenes database. Statistical analyses were performed in R 3.6.0 using the R package heatmap for analysis and graphing. P values ​​were corrected for multiple comparisons using the Benjamini-Hochberg method (p<0.05). miRNA cDNA Synthesis: miRNA cDNA templates were prepared using The TaqMan Advanced miRNA cDNA Synthesis Kit (ThermoFisher Scientific). The miRNA concentration was estimated from isolated total RNA using the Qubit™ microRNA Assay Kit (Invitrogen, ThermoFisher Scientific) to obtain the same concentration in all samples. Poly(A) tailing reaction was performed to elongate the 3' end of the mature transcript.The 5' end was extended by adapter ligation, and the modified miRNA was then subjected to reverse transcription for cDNA synthesis. Amplification of the final products was necessary to increase the cDNA quantity of all miRNAs.

[0058] miRNA Real-Time PCR: Quantification of miRNA expression levels by qPCR analysis was performed using TaqMan Fast Advanced Master Mix (2X) and TaqMan Advanced miRNA Assay (20X) for each miRNA (m¡R-149-5P, m¡R-10A-5P, m¡R-20B-5P, m¡R-30A-3P, m¡R-342-5P) using m¡R-16-5P as the standard. For each miRNA, 15 pl of the PCR reaction mix and 5 pl of diluted cDNA were transferred to each reaction well of the plate. The reaction plate was sealed with an adhesive lid, briefly vertex mixed, and briefly centrifuged to centrifuge the contents. The reaction was performed using a Roche LightCycler 96 thermal cycler, with 20 seconds at 95°C for initial enzyme activation, followed by 45 cycles of 3 seconds at 95°C for denaturation, and 30 seconds at 60°C for annealing and extension. The quantified miRNA expression levels in each sample were normalized.Statistical analysis: The Kruskal-Wallis rank-sum test was used to compare the relative abundance of different bacterial taxa between endometrial cancer patients and healthy individuals, and the false discovery rate (FDR) using the Benjamini-Hochberg method was applied to correct for significant p-values ​​(q-value <0.05). Statistical analyses were performed using SPSS Statistics V.20.0. Continuous variables were compared between groups using the Mann-Whitney U test, while categorical variables were compared using Fisher’s exact test. Spearman’s correlation coefficient was used to estimate correlations between variables. Linear regression analysis was performed to identify individual bacteria as independent predictors of miRNA expression levels in both endometrial cancer subtypes.Values ​​were considered statistically significant when p < 0.05. Clinical characteristics of patients with endometrial cancer vs. healthy controls.

[0059] All clinicopathological characteristics of the endometrial tumors are shown in Table 2. The 58 endometrial tumors analyzed included 30 grade I tumors (51.72%) and 28 grade III tumors (48.27%). Metastasis was detected only in 22 patients with grade III tumors. Regarding histological type, 27 patients had endometrioid carcinoma, while 31 had non-endometrioid carcinoma. Healthy control subjects were matched with the patients by age and BMI. Only 9 patients with endometrial cancer (15.51%) were obese compared to 100% of healthy controls.

[0060] Table 2. Clinicopathological characteristics of patients with endometrial cancer vs. healthy controls.

[0061] Controls Patients with p-value endometrial cancer

[0062] (n=10) (n=58)

[0063] Age at diagnosis (years) 53.10±6.67 56.43±7.88

[0064] 0, 198**

[0065] BMI 22.80 ± 2.25 26.41 ± 6.62

[0066] 0.094**

[0067] Metastasis

[0068] NO 62.07%

[0069] YES 37.93%

[0070] Histological type

[0071] Endometrioid 46.55%

[0072] Non-Endometrioid 53.44% Lymph node*

[0073] Positive 26.66%

[0074] Negative 73.33%

[0075] Stage of the disease*

[0076] I 28.57%

[0077] II 3.57%

[0078] III 42.85%

[0079] IV 25%

[0080] *Patients with Grade I endometrial cancer were not included.

[0081] **Differences were considered significant when the p value was <0.05.

[0082] BMI; body mass index.

[0083] Taxonomic differences in the composition and diversity of the endometrial microbiota between patients with endometrial cancer and healthy controls.

[0084] Analysis of intratumoral samples yielded a total of 2,959,692 16S rRNA gene reads, with an average of 44,174 reads per sample. OTU clustering revealed a total of 12,291 OTUs, but only 1347 OTUs had a relative abundance >1% in at least four samples (97% similarity cutoff) after alignment of representative OTU sequences with QIIME2. Endometrial microbiota in tissue samples was compared between patients with endometrial cancer (EC) and healthy controls (HC). To estimate the alpha diversity of tumor endometrial microbiota components at the genus level within the study groups, the Chaol, Shannon, Simpson, and observed species indices were calculated.A significant increase in diversity and richness indices was observed in endometrial samples from healthy control subjects compared to endometrial cancer patients (Shannon (p = 0.00754), Simpson (p = 0.0037) Species observed (p = 0.001) and Chaol (p = 0.024) (Figures 1A- D).

[0085] Beta diversity analyzed using Bray-Curtis dissimilarity (Figure 1E) also showed significant differences in genus composition between the endometrial cancer groups and healthy controls, showing a separation in the distribution of bacteria in the two groups (p < 0.002, ANOSIM).

[0086] Furthermore, at different taxonomic levels, significant differences in abundance were observed in the endometrial samples of healthy control patients and those with endometrial cancer.

[0087] At the phylum level (Figure 2A), the relative abundance of Verrucomicrobia (p = 0.0098), Bacteroidetes (p = 0.016), Cyanobacteria (p = 0.017), and Actinobacteria (p = 0.036) was significantly increased in healthy controls compared to endometrial cancer patients, whereas the relative abundance of Proteobacteria (p = 0.0043), Firmicutes (p = 0.010), and Deferribacteres (p = 0.036) was significantly increased in endometrial cancer patients. At the family level (Figure 2B), healthy control subjects compared to endometrial cancer patients showed significantly higher abundance of Flavobacteriaceae (p = 0.0086), Prevotellaceae (p < 0.001), Lactobacillaceae (p = 0.031), and S24_7 (p < 0.001), whereas endometrial cancer patients showed significantly higher abundance of Micrococcaceae (p < 0.001), Vibrionaceae (p = 0.010), Corynebacteriaceae (p < 0.001), Propionibacteriaceae (p < 0.001), Staphylococcaceae (p < 0.001), Comamonadaceae (p = 0.029), Lachnospiraceae (p = 0.01) and Nocardiaceae (p < 0.001) with respect to the healthy control group.

[0088] At the general level (Figure 2C), the results show an improvement in the genera Prevotella (p < 0.001), Lactobacillus (p = 0.034), Roseburía (p = 0.0053), AF12 (p = 0.0051), Turícibacter (p = 0.027), Oscillospira (p = 0.011), Blautia (p = 0. 012), Allu baculum (p = 0.019), Ruminococcus (p = 0.037), Akkermancia (p = 0.05), Butyrícimonas (p = 0.0001), Bifidobacterium (p = 0.034), Parabacteroides (p < 0.001) and Mucispirillum (p = 0.012) in the healthy control group in comparison with patients with endometrial cancer. On the other hand, patients with endometrial cancer showed greater abundance of the species Micrococcus (p < 0.001), Propionibacterium (p < 0.001), Staphylococcus (p < 0.001), Pantoea (p < 0.001), Vibrio (p < 0.001), Lawsonia (p < 0.001), Sphingomonas (p < 0.001), Rothia (p = 0.0060), Corynebacterium (p = 0.0095), Ralstonia (p = 0.0013), Paracoccus (p = 0.013) and Pelomonas (p = 0.05) in comparison with their healthy controls.

[0089] Lastly, at the species level ( Figure 2D ), there was a significant increase in the abundance of Prevotella copri (p = 0.007), Lactobacillus reuteri (p = 0.028), Bacteroides acidifaciens (p = 0.028), Parabacteroides distason (p = 0.022) and Mucispirillum schaedleri (p = 0. 034) in the healthy controls group, whereas, in endometrial cancer patients, the relative abundance of other species such as Micrococcus luteus (p = 0.034), Staphilococcus epidermidis (p = 0.015), Propionibacterium (0.001), Propionibacterium acnés (p < 0.001), Photobacterium angustum and Rothia mucilaginosa (p = 0.035) increased significantly.

[0090] A LEfSe analysis was also performed to determine changes in abundant genera between the two study groups. The LEfSe analysis showed that in patients with endometrial cancer, the genera Micrococcus, Staphylococcus, and Propionibacterium were identified as potential intratumoral microbial markers (LDA = 4.0, p < 0.05).

[0091] Taxonomic differences in the composition and diversity of the endometrial microbiota between endometrial cancer subtypes type I (endometrioid carcinoma) and type II (non-endometrioid carcinoma)

[0092] Alpha diversity analysis at the genus level was performed to compare endometrial microbiota communities between the two endometrial cancer subtypes. Significant differences in bacterial richness were observed between endometrioid and non-endometrioid tumors, with significantly increased Chaol (p = 0.0024), Shannon (p = 0.000136), Simpson (p = 0.00027), and observed species (p = 0.00248) indices in endometrioid tumors compared to non-endometrioid tumors (Figures 2A-D). Furthermore, beta diversity analysis using the Bray-Curtis index also showed significant differences in genus composition between the two endometrial cancer types, revealing differences in their gut microbial communities (p = 0.0057, ANOSIM) (Figure 3).

[0093] Furthermore, at different taxonomic levels, significant differences in abundance were observed in the endometrial samples of both subtypes of endometrial cancer.

[0094] At the phylum level (Figure 4A), endometrioid tumors showed higher abundance of Actinobacteria (p < 0.001), Cyanobacteria (p < 0.001), Bacteroidetes (p < 0.001) and Firmicutes (p = 0.0053), while non-endometrioid tumors were enriched by Proteobacteria (p < 0.001).

[0095] At the family level ( Figure 4B ), Ruminococcaceae (p < 0.001), Prevotellaceae (p < 0.001), S24_7 (p < 0.001), Lachnospiraceae (p < 0.001), Bacteroidaceae (p < 0.001), Clostridia (ae (0.01), Bifidobacteriaceae (p < 0.001), Porphyromonadaceae (p = 0.002) and Lactobacillaceae (p = 0.004) were enriched in endometrioid tumors. On the contrary, non-endometrioid tumors showed an increase in Micrococcaceae (p < 0.001), Propionibacteriaceae (p < 0.001 Vibrionaceae (p < 0.001), Fusobacteriaceae (p < 0.001), Staphylococacea (p < 0.001), and Rikenella (p = 0.011), at the genus level (Figure 4C), we found that the abundance of Prevotella (p < 0.001), Faecalibacterium (p = 0.0019), Bifidobacterium (p = 0.0028), Ruminococcus (p = 0.005), Oscilloa (p = 0.06). (p = 0.0074), Fusobacteria (p = 0.039), Lactobacillus (p = 0.010) and Pelomonas were significantly increased in endometrioid tumors.On the other hand, non-endometrioid tumors showed an increase in Micrococcus (p < 0.001), Staphylococcus (p < 0.001), Acinetobacter (p = 0.005), Paracoccus (p = 0.006), Coryne bacterium (p = 0.008), Propionibacterium (p =.

[0096] 0.006 / Porphyromonas (p = 0.039), y Bacteroides (p = 0.039).

[0097] Lastly, at the species level (Figure 4D), a significant excess of Prevotella copri (p < 0.001), Faecalibacterium prausnitzii (p < 0.001), Bacteroides uniformis (p = 0.013), Ruminococcus bromii (p = 0.019), Bacteroides plebeius (p = 0.013), Oscillospira guillermondii (p = 0.013) and Bacteroides caccae (p = 0.037) in endometrioid tumors. On the other hand, the analysis of abundance of species in non-endometrioid tumors revealed an increase in Micrococcus luteus (p < 0.001), Propionibacterium granulosum (p = 0.010) and Propionibacterium acnes (p = 0.036).

[0098] Taxonomic differences in intratumoral microbiota composition and diversity in endometrial patients with and without metastases When comparing the endometrial microbiota in patients with metastatic and non-metastatic endometrial cancer, we found a significant decrease in Shannon diversity (p = 0.00017) and Chaol’s extent (p < 0.001) in metastatic tumors compared to non-metastatic tumors (Figure 5A and 5B). The Bray-Curtis dissimilarity-based ordination plot also showed different endometrial microbial compositions at the genus level between both study groups (p < 0.001, ANOSIM) (Figure 5C).

[0099] Furthermore, significant differences in abundance were observed at different taxonomic levels. At the phylum level, our results indicated a significant enrichment of Bacteroidetes (p < 0.001) and Cyanobacteria (p < 0.001) in non-metastatic tumors, whereas metastatic tumors were significantly enriched with Fusobacteria (p < 0.001) (Figure 5D).

[0100] At the genus level, the relative abundance of Blautia (p < 0.001), Faecalibacterium (p < 0.001), Prevotella (p < 0.001), Ruminococcus (p < 0.001), Bifidobacterium (p < 0.001), Bacteroides (p < 0.001), Lactobacillus (p < 0.001). 0.001) and Oscillospira (p < 0.001) increased in non-metastatic tumors. While metastatic tumors showed a significantly higher abundance of Micrococcus ( p < 0.001), Pantoea ( p < 0.001), Propionibacterium ( p < 0.001), Paracoccus ( p < 0. 001), Acinetobacter ( p < 0.001), Staphylococcus ( p < 0.001), Fusobacterium ( p < 0.001), Ralstonia ( p < 0.001) and Corynebacterium ( p < 0.001) ( Figure 5F ).

[0101] Finally, at the species level, our analysis suggested that the abundance of Prevotella copri (p < 0.001), Faecalibacterium prausnitzii (p < 0.001), Bacteroides plebeius (p < 0.001), and Bacteroides uniformis (p < 0.001) was significantly increased in non-metastatic tumors. On the other hand, metastatic tumors showed an elevated abundance of Propionibacterium granulosum (p < 0.001), Propionibacterium acnes (p < 0.001), Staphylococcus epidermis (p < 0.001), and Micrococcus luteus (p < 0.001).

[0102] =0.012) (Figure 5E).

[0103] Expression of miRNAs

[0104] The expression profiles of the five miRNAs of the invention (m¡R149-5p, m¡R10a-5p, m¡R20b-5p, m¡R30a-3p and m¡R342-5p) were determined in endometrial tumor tissue samples by qRT-PCR. When comparing the miRNA expression levels between endometrioid and non-endometrioid tumor samples, our results showed a significant increase of m¡R149-5p (p < 0.001) and m¡R20b-5p (p = 0.003) in endometrioid tumor samples compared to non-endometrioid ones (Figure 6).

[0105] On the other hand, the comparison between metastatic and non-metastatic tumors revealed a significant increase in the expression of m¡R20b-5p (p = 0.05) and a decrease in the expression of m¡R10a-5p (p

[0106] = 0.011) in metastatic tumors compared to non-metastatic tumors (Figure 7).

[0107] Correlation between miRNAs and endometrial cancer microbiota groups

[0108] Significant expression correlations of m¡R149-5p and m¡R20b-5p in endometrioid and non-endometrioid patients with the endometrial cancer microbiota at the genus level were performed. Statistical analysis revealed the relationship between miRNAs and several bacterial genera. The correlation results were summarized in Table 3.

[0109] Table 3. Analysis of the correlation between miRNAs and cancer microbiota at the genus level in endometrioid and non-endometrioid patients. miRNA 149-5 miRNA 20b-5p

[0110] Endometrioid Non-endometrioid Endometrioid Non-endometrioid

[0111] Bacteroids 0.741 (p=0.035) -0.653 (p=0.040)

[0112] Blautia 0.676 (p=0.042)) 0.711 (p=0.05) -0.690 (p=0.05) -0.723 (p=0.039)

[0113] Faecalibacterium 0.792 (p=0.021) 0.801 (p=0.039) -0.794 (p=0.030) -0.641 (p=0.048)

[0114] Ruminococcus 0.811 (p=0.001) 0.834 (p=0.041) -0.891 (p=0.001) -0.811 (p=0.020)

[0115] Lactobacillus 0.890(p=0.003) 0.763(p=0.023) -0.851 (p=0.018) -0.863(p=0.023)

[0116] Oscillospira 0.706(p=0.022) -0.769 (p=0.025)

[0117] Fusobacteríum -0.869 (p=0.012) -0.891 (p=0.001) 0.865 (p=0.002) 0.891 (p=0.001)

[0118] Staphylococcus -0.849 (p=0.039) -0.863(p=0.027) 0.831 (p=0.023) 0.863(p=0.027)

[0119] Micrococcus -0.738 (p=0.027) -0.648 (p=0.029) 0.731 (p=0.019) 0.648 (p=0.029)

[0120] Propionibacteríum -0.653 (p=0.040) 0.653 (p=0.040)

[0121] Porphyromonas -0.841 (p=0.015) 0.803 (p=0.019)

[0122] Subsequent linear regression analysis showed that the relative abundances of Staphylococcus (R2 = 0.952 p = 0.522 p = 0.001), Fusobacterium (R2 = 0.33, p = 0.978, p = 0.003), Porphyromonas (R2 = 0. 952 p = 0.845, p= 0.011) and Micrococcus (R2 = 0.952 p = 0.790, p< 0.001) were positively associated with the tumor m¡RNA20b-5p expression level in non-endometrioid patients. While the abundance of Lactobacillus (R2 = 0.952 p = 0.567 p = 0.001) and Ruminococcus (R2 = 0.33, p = 0.978, p = 0.003) was positively associated with the tumor expression level of m¡RNA149-5p in endometrioid patients.

[0123] Similarly, regression analysis showed that in non-metastatic patients, the expression level of miRNA10a-5p was positively associated with the abundance of Ruminococcus (R2 = 0.865, p = 1.105, p = 0.003), Bifidobacterium (R2 = 0.865, p = 1.160, p < 0.001), Lactobacillus (R2 = 0.865, p = 1.105, p = 0.003) and Faecalibacterium (R2 = 0.865, p = 0.631, p = 0.012), while the expression level of miRNA20b-5p was positively associated with the abundance of Fusobacterium (R2 = 0.865, p = 2.084, p < 0.001). 0.001) and Micrococcus (R2 = 0.865, p = 0.984, p = 0.039) in metastatic patients.

[0124] Table 4. Correlation analysis between significant miRNAs and metastatic and non-metastatic microbiota at the genus level. miR10a-5p miR20a-5p

[0125] Metastatic Non-metastatic Metastatic Non-metastatic

[0126] Bacteroides 0.811 (p=0.017) 0.656 (p=0.032) -0.641 (p=0.017) -0.568 (p=0.041)

[0127] Bilophila 0.767 (p=0.011) 0.706 (p=0.029) -0.767 (p=0.011) -0.728 (p=0.036)

[0128] Faecalibacterium 0.684 (p=0.008) 0.815 (p=0.016) -0.703 (p=0.037) -0.821 (p=0.006)

[0129] Ruminococcus 0.784 (p=0.018) 0.801 (p=0.006) -0.671 (p=0.038) -0.760 (p=0.019)

[0130] Lactobacillus 0.847 (p=0.001) 0.837 (p=0.028) -0.841 (p=0.021) -0.761 (p=0.026) Butyricimonas 0.572 (p=0.01) -0.478 (p=0.048)

[0131] Bifidobacterium 0.843 (P=0.016) 0.707 (p=0.005) -0.759 (p=0.026) -0.851 (p=0.001)

[0132] Fusobacterium -0.731 (p=0.029) -0.931 (p=0.012) 0.765 (p=0.039) 0.912 (p=0.022)

[0133] Staphylococcus -0.885 (p=0.037) 0.707 (p=0.027) Micrococcus -0.670 (p=0.037) -0.707 (p=0.029) 0.750 (p=0.029) 0.640 (p=0.038)

[0134] Propionibacterium -0.798 (p=0.032) 0.902=0.015)

[0135] The composition of the initial intratumoral endometrial microbiota and the expression levels of tumor miRNAs as predictors of the development of metastasis in patients with endometrial cancer.

[0136] For this analysis, the Random Forest method was used to build a species-level predictive model to identify features based on the initial composition of the intratumoral microbiota and the expression levels of tumor miRNAs that discriminate between endometrial patients who develop metastases and those who do not.

[0137] To do this, first, receiver operating characteristic (ROC) curves were independently calculated for the predominant intratumoral microbial species and for the intratumoral expression level of the 5 miRNAs in Table 1, in patients with endometrial cancer with and without metastasis.

[0138] Receiver operating characteristic (ROC) curves using the predominant intratumoral microbial taxa in patients with endometrial cancer with and without metastasis showed that only with these 5 genera, Bifidobacterium, Faecalibacterium, Fusobacterium, Micrococcus and Lactobacillus, the AUG was 0.903 (95% confidence interval: 0.822-0.984).

[0139] Thus, at the species level (Figure 8A), the AUG was 0.903 (95% confidence interval: 0.822–0.984) and the main species responsible for this stratification were Bifidobacterium longum, Faecalibacterium prausnitzii, Fusobacterium nucleatum, Micrococcus luteus and Lactobacillus mucosae.

[0140] By adding the following 5 miRNAs to the model containing the 5 genera, Bifidobacterium, Faecalibacterium, Fusobacterium, Micrococcus and Lactobacillus: m¡R149-5p, m¡R10a-5p, m¡R20b-5p, m¡R30a-3p and m¡R342-5p, the AUG was 0.828 (95% confidence interval: 0.712-0.943) (Figure 8B), with m¡R20b-5p and m¡R10a-5p contributing the most to this model.

[0141] These data indicate that both diagnostic models have an acceptable level of accuracy in predicting metastasis.

[0142] The diagnostic model that showed the best predictive capacity for the appearance of metastasis and the highest level of accuracy is the one that jointly includes the 5 intratumoral species (Bifidobacterium longum, Faecalibacterium prausnitzii, Fusobacterium nucleatum, Micrococcus luteus and Lactobacillus mucosae) and the 2 miRNAs (m¡R20b-5p and m¡R10a-5p), showing an AUG of 0.926 (95% confidence interval: 0.857–0.994, Figure 8C). With these results, we can conclude that there is a microbiota profile associated with each of the endometrial cancer subtypes and different from that present in the endometrial tissue of healthy controls. It also demonstrates how the decrease in bacterial diversity and richness is associated with a worse prognosis in patients with endometrial cancer, such as the non-endometrioid subtype.

[0143] The microbiota of patients with endometrial cancer is characterized by a reduction in butyrate and lactate-producing bacteria (Lactobacillus, Akkermansia, Bifidobacterium and Faecalibacterium) and an increase in opportunistic pathogens (Micrococcus, Propionibacterium, Staphylococcus, Pseudomonas and Fusobacterium).

[0144] The relative abundance of these opportunistic pathogens was significantly higher in patients with the non-endometrioid subtype compared with patients with the endometrioid subtype.

[0145] Finally, there is a miRNA expression profile associated with each of the endometrial cancer subtypes. MiR20b-5p, involved in promoting cell proliferation and migration, was positively correlated with the abundance of opportunistic pathogens such as Staphylococcus, Fusobacterium, and Micrococcus in non-endometrioid patients, while miR149-5p, involved in tumor suppression and metastasis inhibition, was positively correlated with the abundance of Lactobacillus and Ruminococcus in patients with endometrioid cancer.

[0146] These data show an important connection between miRNA expression and intratumoral microbiota composition and support the role of miRNAs in mediating host-microbiome interactions proposing that gut microbiota is able to induce or suppress miRNAs in the human body, but also host miRNAs can regulate bacterial growth and influence gut microbiota composition.

[0147] References

[0148] 1. Barra F, Evangelisti G, Ferro Desideri L, Di Domenico S, Ferraioli D, Vellone VG, De Cian F, Ferrero S. Investigational PI3K / AKT / mTOR inhibitors in development for endometrial cancer. Expert Opinion Investig Drugs. 2019 Feb;28(2):131-142.

[0149] 2. Walther-António, M.R.S.; Chen, J.; Multinu, F.; Hokenstad, A.; Distad, T.J.; Cheek, E.H.; Keeney, G.L.; Creedon, D.J.; Nelson, H.; Mariani, A.; et al. Potential Contribution of the Uterine Microbiome in the Development of Endometrial Cancer. Genome Medicine 2016, 8, 122, doi:10.1186 / s13073-016-0368-y.

[0150] 3. Walsh, D.M., Hokenstad, A.N., Chen, J. et al. Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome). Sci Rep 2019; 9:19213

[0151] 4. Leonardi, M, Hicks, C, El-Assaad, F, El-Omar, E, Condous, G. Endometriosis and the microbiome: a systematic review. BJOG 2020; 127: 239- 249. 5. Pelzer, E.S.; Willner, D.; Buttini, M.; Huygens, F. A Role for the Endometrial Microbiome in Dysfunctional Menstrual Bleeding. Antonie Van Leeuwenhoek 2018, 111 , 933-943, doi:10.1007 / s10482- 017-0992-6.

[0152] 6. MITCHELL, C.M.; HAICK, A.; NKWOPARA, E.; GARCIA, R.; RENDI, M.; AGNEW, K.; FREDRICKS, D.N.; ESCHENBACH, D. Colonization of the Lipper Genital Tract by Vaginal Bacterial Species in Non¬

[0153] Pregnant Women. Am J Obstet Gynecol 2015, 212, 611 ,e1-611 ,e9, doi: 10.1016 / j.ajog .2014.11 .043.

[0154] 8. Eulalio, A.; Schulte, L.; Vogel, J. The Mammalian MicroRNA Response to Bacterial Infections. RNA Biology 2012, 9, 742-750, doi:10.4161 / rna.20018.

[0155] 9. Altered MicroRNA Expression Levels in Mononuclear Cells of Patients with Pulmonary and Pleural Tuberculosis and Their Relation with Components of the Immune Response | Elsevier Enhanced Reader

[0156] Available online: https: / / reader.elsevier.com / reader / sd / pii / S0161589012003677?token=DB5D5D46C801972A87A058E727 BD601 D636E068C2836C7B6C2F01 B1A731 CFCF08FB04CA0C0D55C7B30446E05910DD31 E&originR egion=eu-west-1&originCreation=20220413134104 (accessed on 13 April 2022).

Claims

CLAIMS 1. Combined use of relative abundance values ​​of the genera Bifidobacterium, Faecalibacterium, Lactobacillus, Fusobacterium, Micrococcus in the microbiota present in a previously isolated endometrial sample and the expression levels of m¡R149-5p, miR10a-5p, m¡R20b-5p, m¡R30a-3p and m¡R342-5p in a previously isolated endometrial sample as biomarkers for the diagnosis and / or prognosis of metastasis in patients with endometrial cancer.

2. The combined use of the biomarkers according to the preceding claim, where within said genera the following species are selected: Bifidobacterium longum, Faecalibacterium prausnitzii, Fusobacterium nucleatum, Micrococcus luteus and Lactobacillus mucosae, and where, within the miRNAs, m¡R20b-5p and m¡R10a-5p are selected.

3. An in vitro method for obtaining data useful for diagnosing and / or predicting metastasis in patients with endometrial cancer that includes:a) isolating the genetic material of the microbiota present in a previously isolated sample of endometrium, b) taxonomically identifying the isolated genetic material and quantifying the relative abundance of the genera Bifidobacterium, Faecalibacterium, Lactobacillus, Fusobacterium and Micrococcus in the sample, and c) comparing the relative abundance of the genera identified in step b) with that of a reference sample from a patient with endometrial cancer who does not present metastasis, and which also comprises, simultaneously or sequentially, d) quantifying in the previously isolated sample of endometrium the expression levels of miR149-5p, m¡R10a-5p, m¡R20b-5p, m¡R30a-3p and m¡R342-5p, and e) comparing the expression levels of the miRNAs from step d) with those of a reference sample from a patient with endometrial cancer who does not present metastasis.

4. An in vitro method for obtaining data useful for diagnosing and / or predicting metastasis in patients with endometrial cancer, comprising: a) isolating the genetic material from the microbiota present in a previously isolated sample of endometrium, b) taxonomically identifying the isolated genetic material and quantifying the relative abundance of the species Bifidobacterium longum, Faecalibacterium prausnitzii, Fusobacterium nucleatum, Micrococcus luteus and Lactobacillus mucosae in the sample, and c) comparing the relative abundance of the species identified in step b) with that of a reference sample from a patient with endometrial cancer who does not present metastasis, and which also comprises, simultaneously or sequentially, d) quantify the expression levels of miR20b-5p and miR10a-5p in the previously isolated endometrium sample, and e) compare the expression levels of the miRNAs from step d) with those of a reference sample from a patient with endometrial cancer who does not present metastasis.

5. An in vitro method for diagnosing and / or predicting metastasis in patients with endometrial cancer comprising the method according to claim 3, further comprising f) classifying the patient into the group of patients who have developed or are at risk of developing metastasis if, with respect to the reference sample, the relative abundance in the sample of the genera Bifidobacterium, Faecalibacterium, and Lactobacillus is significantly lower, the relative abundance of the genera Fusobacterium, Micrococcus is significantly higher, the expression levels of m¡R20b-5p, m¡R149-5p and m¡R342-5p are increased and the expression levels of m¡R10a-5p and m¡R30a-3p are decreased.

6. An in vitro method for diagnosing and / or predicting metastasis in patients with endometrial cancer comprising the method according to claim 4, further comprising f) classifying the patient into the group of patients who have developed or are at risk of developing metastasis if, with respect to the reference sample, the relative abundance in the sample of the species Bifidobacterium longum, Faecalibacterium prausnitzii and Lactobcillus mucosae is significantly lower, the relative abundance of the species Fusobacterium nucleatum, and Micrococcus luteus is significantly higher, the expression levels of m¡R20b-5p are increased and the expression levels of m¡R10a-5p are decreased.

7. The method according to any of claims 3 to 6, characterized in that the level of expression of the miRNAs is obtained by: (i) a miRNA profiling method, such as a microarray, and / or (i) a method comprising PCR (polymerase chain reaction), such as real-time PCR or RT-PCR and / or (iii) a Northern Blot and / or (iv) an immunoassay, such as an immunohistochemical method or an ELISA-based method.

8. A kit or device comprising at least one or more oligonucleotides capable of hybridizing with each of the miRNAs m¡R149-5p, m¡R10a-5p, m¡R20b-5p, m¡R30a-3p and m¡R342-5p, simultaneously, under stringent conditions.

9. Use of the kit of claim 8 to carry out step d) of the method according to any of claims 3 to 6.

Citation Information

Patent Citations

  • Microrna signature as an indicator of the risk of early recurrence in patients with breast cancer

    WO2015136141A1